GlaxoSmithKline Pharmaceuticals Limited annual earnings per share (EPS) for fiscal 2026 was ₹61.15, an increase of 11.7% from ₹54.76 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Diluted EPS | ₹61M | ₹55M | ₹35M | ₹36M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Diluted EPS | ₹14M | ₹16M | ₹17M | ₹12M | ₹16M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More GLAXO metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow
All GLAXO financial statements → Interactive GLAXO charts →
About TickerBase · Data methodology & sources · Privacy · Terms